Tarhan Yunus Emre, Kato Taigo, Jang Miran, Haga Yoshimi, Ueda Koji, Nakamura Yusuke, Park Jae-Hyun
Department of Medicine, The University of Chicago, Chicago, IL 60637, USA.
Cancer Proteomics Group, Genome Center, Japanese Foundation for Cancer Research, Tokyo, 135-8550, Japan.
Neoplasia. 2016 May;18(5):265-272. doi: 10.1016/j.neo.2016.03.005. Epub 2016 Apr 15.
Pancreatic cancer reveals the worst prognosis among human cancers with little improvement in its clinical outcome in the last three decades. We previously suggested that polypeptide N-acetylgalactosaminyltransferase 6 (GALNT6), which catalyzes O-type glycosylation of Mucin 1, might be a promising molecular target for drug development for breast cancer. In this study, we report upregulation of GALNT6 in pancreatic cancer cells where Mucin proteins are highly O-glycosylated. We found that knockdown of GALNT6 with small interfering RNA in pancreatic cancer cells decreased the amount of Mucin 4 protein as well as that of its transcript, reduced the levels of human epidermal growth factor receptor 2 and extracellular signal-regulated kinase, and significantly reduced pancreatic cancer cell viability. Interestingly, knockdown of GALNT6 caused drastic morphological changes of pancreatic cells, accompanied with the cadherin switching from P-cadherin to E-cadherin. Considering important roles of Mucin 4 in growth and invasion, our findings imply that targeting GALNT6 is a very promising therapeutic strategy for treatment of pancreatic cancer patients who still have very limited treatment modalities.
在人类癌症中,胰腺癌的预后最差,在过去三十年里其临床结局几乎没有改善。我们之前曾提出,催化黏蛋白1 O型糖基化的多肽N-乙酰半乳糖胺基转移酶6(GALNT6)可能是乳腺癌药物开发的一个有前景的分子靶点。在本研究中,我们报告了GALNT6在黏蛋白蛋白高度O-糖基化的胰腺癌细胞中的上调。我们发现,用小干扰RNA敲低胰腺癌细胞中的GALNT6会减少黏蛋白4蛋白及其转录本的量,降低人表皮生长因子受体2和细胞外信号调节激酶的水平,并显著降低胰腺癌细胞的活力。有趣的是,敲低GALNT6会导致胰腺细胞发生剧烈的形态变化,同时伴随着钙黏蛋白从P-钙黏蛋白转变为E-钙黏蛋白。鉴于黏蛋白4在生长和侵袭中的重要作用,我们的研究结果表明,针对GALNT6进行靶向治疗是治疗治疗方式仍然非常有限的胰腺癌患者的一种非常有前景的治疗策略。